South Korea · Delayed Price · Currency is KRW Pharos iBio Statistics
Total Valuation
Pharos iBio has a market cap or net worth of KRW 61.43 billion. The enterprise value is 51.87 billion.
| Market Cap | 61.43B |
| Enterprise Value | 51.87B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 2.28% in one year.
| Current Share Class | 12.95M |
| Shares Outstanding | 12.95M |
| Shares Change (YoY) | +2.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 30.10% |
| Owned by Institutions (%) | n/a |
| Float | 9.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.74 |
| P/TBV Ratio | 4.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.93 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.73 |
Financial Position
The company has a current ratio of 17.10, with a Debt / Equity ratio of 0.02.
| Current Ratio | 17.10 |
| Quick Ratio | 16.30 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,866.82 |
Financial Efficiency
Return on equity (ROE) is -58.74% and return on invested capital (ROIC) is -39.57%.
| Return on Equity (ROE) | -58.74% |
| Return on Assets (ROA) | -38.33% |
| Return on Invested Capital (ROIC) | -39.57% |
| Return on Capital Employed (ROCE) | -87.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -318.94M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.37% in the last 52 weeks. The beta is 0.17, so Pharos iBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -41.37% |
| 50-Day Moving Average | 5,724.40 |
| 200-Day Moving Average | 6,693.30 |
| Relative Strength Index (RSI) | 33.94 |
| Average Volume (20 Days) | 100,747 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -15.91M |
| Operating Income | -11.50B |
| Pretax Income | -10.53B |
| Net Income | -10.53B |
| EBITDA | -10.67B |
| EBIT | -11.50B |
| Earnings Per Share (EPS) | -813.61 |
Balance Sheet
The company has 9.84 billion in cash and 285.89 million in debt, giving a net cash position of 9.55 billion or 737.99 per share.
| Cash & Cash Equivalents | 9.84B |
| Total Debt | 285.89M |
| Net Cash | 9.55B |
| Net Cash Per Share | 737.99 |
| Equity (Book Value) | 12.96B |
| Book Value Per Share | 1,001.34 |
| Working Capital | 9.84B |
Cash Flow
In the last 12 months, operating cash flow was -8.76 billion and capital expenditures -287.76 million, giving a free cash flow of -9.05 billion.
| Operating Cash Flow | -8.76B |
| Capital Expenditures | -287.76M |
| Free Cash Flow | -9.05B |
| FCF Per Share | -698.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharos iBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.28% |
| Shareholder Yield | -2.28% |
| Earnings Yield | -17.13% |
| FCF Yield | -14.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |